Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back Pain

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

138 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate efficacy of Finalgon® cream (1.08% Nicoboxil/ 0.17% Nonivamide) versus placebo in patients with acute low back pain. To investigate the safety and tolerability of repeated use of Finalgon® cream (1.08% Nicoboxil/ 0.17% Nonivamide).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nonivamide/Nicoboxil Ointment in Acute Low Back Pain

NCT01708915

Acute Low Back Pain

COMPLETED PHASE3

Comparison of the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component

NCT01166048

Chronic Low Back Pain

COMPLETED PHASE4

Capsaicin + Diclofenac Gel in Acute Back Pain or Neck Pain

NCT02700815

Acute Pain

COMPLETED PHASE3

Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

NCT05096494

Moderate to Severe Acute Lower Back Pain

COMPLETED PHASE2

Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component

NCT01838044

Chronic Low Back Pain With a Neuropathic Component

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Low Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

nonivamide + nicoboxil (Finalgon cream)

2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period

Group Type EXPERIMENTAL

nonivamide + nicoboxil (Finalgon cream)

Intervention Type DRUG

2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period

placebo

2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period

Group Type PLACEBO_COMPARATOR

placebo matching nonivamide + nicoboxil (Finalgon cream)

Intervention Type DRUG

2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nonivamide + nicoboxil (Finalgon cream)

2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period

Intervention Type DRUG

placebo matching nonivamide + nicoboxil (Finalgon cream)

2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients must sign and date an Informed Consent consistent with International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) guidelines and local regulation prior to participation in the trial.
2. Patients must agree to cooperate with all trial evaluations and perform all required tasks.
3. Patients must have acute nonspecific low back pain, ICD-10 code: M54.5.
4. Patients must have acute low back pain for more than 2 days and less than 21 days (= 3 weeks).
5. Male or female more or equal 18 and less or equal 65 years of age at Visit 1(Baseline).
6. Low back pain Pain intensity more or equal 5 on a 0-10 numerical rating scale (NRS).

Exclusion Criteria

1. Patients with a significant disease other than acute nonspecific low back pain. A significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the trial, or (ii) influence the results of the trial, or (iii) cause concern regarding the patient's ability to participate in the trial.
2. Multilocular pain or panalgesia.
3. History of more than 3 low back pain episodes in the last 6 months.
4. Acute low back pain due to vertebral collapse or neoplastic, inflammatory (ankylosing spondylitis), traumatic, or infective origins.
5. Abnormal findings in at least one of the following assessments: Achilles tendon reflex, patella reflex, heel walking, toe walking, cutaneous sensitivity of the legs (including gluteal region), paresis tests in supine position upon dorsiflexion, plantarflexion, hip flexion, knee extension.
6. Neurogenic Bladder and/or rectum dysfunction.
7. Any condition, disease or concomitant treatment that in the judgement of the investigator will affect the patient's ability to participate in the clinical trial or which will influence the trial methodology used.
8. Negative experience in the past with heat treatment for muscle complaints (e. g. hot water bottle, heat pads, hyperemisation-inducing topical creams, ointments or patches).
9. Patients with history of treatment of back pain with centrally acting drugs (e.g. opioids) and muscle relaxants within 6 months prior to enrolment.
10. Surgery due to back pain or rehabilitation due to back pain in the last 12 months.
11. Spinal injection back pain treatment within 6 months prior to enrolment.
12. Intake of antidepressant/antipsychotic medication within 4 weeks prior to enrolment.
13. Treatment of the recent low back pain period with oral analgesics for more than 4 consecutive days.
14. Locally applied medication to the back within 24 hours prior to enrolment (topical treatments, injections).
15. Non-pharmacological low back pain treatment (physiotherapy, heat treatment \[e.g. hot water bottle, heat patch\], or massages) within 12 hours prior to enrolment.
16. Administration of other analgesics within 12 h prior to enrolment (exception: acetylsalicylic acid \[ASS\] up to 100 mg/daily for anti-platelet-aggregation therapy).
17. Non-pharmacological low back pain treatment (physiotherapy, heat treatment \[e.g. hot water bottle, heat patch\], or massages) within 12 hours prior to enrolment.
18. Participation in an investigational drug or device trial within 4 weeks prior to enrolment.
19. History of treatment of back pain with centrally acting drugs (e.g. opioids) and muscle relaxants.
20. Treatment of the recent low back pain period with oral analgesics for more than 4 consecutive days.
21. Surgery due to back pain or rehabilitation due to back pain in the last 12 months.
22. Spinal injection back pain treatment within 6 months prior to enrolment.
23. Intake of antidepressant/antipsychotic medication within 4 weeks prior to enrolment.
24. Known hypersensitivity to nicoboxil, nonivamide, or other ingredients of the cream.
25. Known hypersensitivity to paracetamol.
26. Skin lesions (e.g. rash, bruising, laceration) in the back region.
27. Known history of central nervous system diseases with severe intellectual and memory disorders, psychiatric disorders.
28. History of abuse of alcohol/drugs within six months prior to enrolment.
29. Acute and relapsed chronic kidney diseases.
30. Severe hepatocellular insufficiency.
31. Pregnant or nursing women, including female patients with positive ß-HCG test at Visit 1.
32. Female patients of child-bearing potential not using highly effective method of birth control.
33. Patients who are currently participating in another trial or who have been participating in another trial within one month prior to Visit 1, and patients who have previously been randomised in this trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No